GENFIT Sets November 8 Event to Detail Nangibotide Phase 2 Push in ACLF

GENFIT will host a scientific event on November 8, 2026, to outline its strategy in acute-on-chronic liver failure and present the clinical data package supporting nangibotide's advancement into Phase 2 in that indication, the company said in a November 2 announcement. The FinancialContent Business Page carried the announcement.

GENFIT's November 8 ACLF Scientific Event

GENFIT is a Lille, France-based biopharmaceutical company that develops therapies and diagnostics for rare and life-threatening liver diseases and generates revenue mainly through royalties and milestones from Ipsen's commercialization of Iqirvo (elafibranor) for Primary Biliary Cholangitis. The November 8 event will feature Professor Jennifer Lai of UC San Francisco as a guest speaker and will review nangibotide, a TREM-1 modulator. The development package includes clinical evidence at the proposed dose, available clinical supply and regulatory data informing the decision to advance into Phase 2 in ACLF.

Three posters will be presented on November 6, 2026, from 1:00 to 2:00 p.m. MT. Poster #2284 covers RIPK1 inhibition and NET release in hemorrhagic liver injury in mice, poster #2273 covers emergency granulopoiesis-like signatures across the bone marrow, spleen and liver axis, and poster #2034 covers ex vivo blood assays of G1090N, a novel formulation of nitazoxanide, supporting further clinical evaluation in ACLF. NACSELD, a North American research consortium focused on cirrhosis and ACLF, will host a dedicated scientific meeting on November 5, 2026, chaired by Professor Jasmohan S. Bajaj of Virginia Commonwealth University, where GENFIT management will present its ACLF strategy.

GENFIT's MASH Diagnostics Forum Role

GENFIT is taking a leading role in the Global Liver Institute's Beyond the Biopsy National Implementation Forum on November 4, 2026, which brings together drug manufacturers including Novo Nordisk, Eli Lilly and Madrigal as well as key opinion leaders. Larry Holden, CEO of the Global Liver Institute, said: "We are reaching an important inflection point in MASH: effective treatments are becoming available, making the ability to identify the right patients, particularly those with at-risk MASH, increasingly critical." GENFIT's expert panel on November 6, 2026, will address non-invasive testing for at-risk MASH and the potential of its NIS Technology, with Ashley Hamilton Chasick, global lead of diagnostics partnerships at Novo Nordisk, giving an industry view.

GENFIT's Nitazoxanide Designation and Financing

According to akta.pro company records, the FDA granted Orphan Drug Designation to NTZ/G1090N, a nitazoxanide reformulation, for ACLF in March 2026, securing development incentives, user-fee reductions and seven-year U.S. market exclusivity upon approval. The same records show GENFIT activated an additional €30 million tranche under its royalty-financing agreement with HCRx in January 2026, extending its cash runway beyond the end of 2028.

GENFIT's Path to the Liver Meeting

GENFIT announced in September 2026 that it had acquired nangibotide in summer 2026 and planned a Phase 2 proof-of-concept trial in ACLF, Yahoo reported. GENFIT reported first-half 2026 results with €21.1 million in revenue, a €26.1 million net loss and €113.8 million in cash, and said it expects to fund operations beyond 2028, the FinancialContent Business Page reported. The company entered the SBF 120 index on September 18, 2026, Les Echos reported.

What Comes After the Liver Meeting

GENFIT's partner Ipsen is also expected to communicate on elafibranor during The Liver Meeting 2026, according to the company's announcement.